Indian pharmaceutical multinational Cipla's U.K. arm, Cipla (EU) Limited, acquired U.S.-based InvaGen Pharmaceuticals and Exelan Pharmaceuticals.
Indian drug manufacturer Ranbaxy Laboratories was warned and asked to account by the South African government after finding a potentially harmful active ingredient in folic acid tablets sold by the company.
An investment of $225 million will see China investor-backed Athenex make active pharmaceutical ingredients (APIs) and oncology in western New York state and ship products to China and the world.
India's government plans to release the country's new policy on bulk drugs in a month, Minister of State Ministry of Chemicals and Fertilizers Hansraj Ahir said during Mumbai's weeklong Make in India event.
GlaxoSmithKline plans to invest INR500 million ($73 million) in an upgrade of its manufacturing plant in Nashik northeast of the India financial capital Mumbai to build up output of thyroid and dermatology products, the Business Standard reports.
China's leadership renewed a push to winnow out bad quality drug manufacturers and improve safety as part of a State Council meeting that updated on an ambitious program of healthcare reforms calling for access to newer therapies and greater use of traditional Chinese medicines (TCM).
Shanghai-founded MicroPort, or fellow China-based Mindray Medical, are not exactly household healthcare names--but along with other players they are China's leading device and healthcare service firms abroad and are a growing competition to multinational and local companies.
The administration of Indonesian President Joko Widodo has cleared the decks for foreign firms to own 100% of active pharmaceutical ingredient (API) operations, eliminating a 85% threshold that also required a local partner.
Contract drugmaker Recipharm is promising to spend $45 million (€40 million) over the next three years to improve drug traceability in an effort to comply with new regulations and combat the rise of fake medicines.
The government of Japan is changing the lucrative brand-name healthcare market as its population ages and requires more drugs with a push to make at least 80% of the government's drug spending be for generics.